Cardiac metabolism as a target for the treatment of heart failure.
Heinrich
H
Taegtmeyer
D000083:Acetanilides; D000818:Animals; D004285:Dogs; D004734:Energy Metabolism / Q000187:drug effects; D004852:Epoxy Compounds / Q000494:pharmacology / Q000627:therapeutic use; D005227:Fatty Acids / Q000378:metabolism; D005544:Forecasting; D005934:Glucagon / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D009206:Myocardium / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011498:Protein Precursors / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D000069458:Ranolazine; D011994:Recombinant Proteins / Q000627:therapeutic use
D000083:Acetanilides; D004852:Epoxy Compounds; D005227:Fatty Acids; D010446:Peptide Fragments; D010879:Piperazines; D011498:Protein Precursors; D011994:Recombinant Proteins; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000069458:Ranolazine; D005947:Glucose; C054207:etomoxir